Citations

Clear

9383 citation(s) found for "Thomas, PS".

Prognostic Factors in Limited-Stage Small Cell Lung Cancer
Farris, Michael K., Mix, M. , Wang, Xiaofei , Jaszewski, Brandy L., Foster, Nathan R. , Laurie, Fran, Smith, Koren, Alden, Ryan S. , Komaki, Ritsuko , Stinchcombe, Thomas E. , Bradley, Jeffrey D. , Bogart, Jeffrey A. , Jaszewski, Brandy, Bradley, Jeffrey , Farris, Michael K , Masters, Gregory A. , Razavian, Niema B , Vokes, Everett E.

Mayo Clinic

JAMA Network Open | October 24, 2024 | Volume: 7 | Issue: 10 | Pages: e2440673

10.1001/jamanetworkopen.2024.40673 | PMID 39446327 Get It

Importance The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors from the Cancer and Leukemia Group B (CALGB) 30610–Radiation Therapy Oncology Group (RTOG) 0538 trial may impact future trial design. Objective To assess the comprehensive demographic, disease-related, treatment-related, and social factors for potential associations with survival outcomes and understand whether specific subpopulations may benefit from radiotherapy (RT) dose escalation in LS-SCLC. Design, Setting, and Participants This post hoc secondary analysis of a randomized clinical trial included 638 adults with LS-SCLC treated at 186 unique treatment sites with at least 1 accrual for all patients from March 15, 2008, to December 1, 2019; 313 patients were randomized to receive RT twice daily to a dosage of 45 Gy for 3 weeks and 325 to receive RT once daily to a dosage of 70 Gy for 7 weeks. Data were locked February 28, 2022, and analyzed from November 28, 2022, to June 4, 2024. Interventions Twice-daily RT or once-daily RT. Main Outcomes and Measures Multivariable Cox proportional hazards models evaluated the association of treatment groups and other risk factors with progression-free survival (PFS) and overall survival (OS). Patient-specific factors included age, sex, and Eastern Cooperative Oncology Group performance status. Disease-related factors included tumor, nodal, and overall cancer stages. Treatment-related factors included type of chemotherapy, timing of concurrent RT, RT technique, and prophylactic cranial irradiation. Social factors included marital status and treatment center accrual volume. Results Among 507 patients (260 [51.3%] female and 247 [48.7%] male; mean [SD] age, 62.6 [7.9] years) included in the multivariate survival analysis, with a median follow-up of 4.7 (IQR, 3.7-7.1) years, female sex was associated with improved OS (hazard ratio [HR], 0.73 [95% CI, 0.58-0.91]; P = .006), while being 70 years or older was associated with decreased OS (HR, 1.50 [95% CI, 1.14-1.98]; P = .004). Neither age nor sex was associated with PFS. When compared with those with N1 disease, OS and PFS were worse in patients with N2 (HRs, 1.64 [95% CI, 1.19-2.26]; P = .002 and 1.36 [95% CI, 1.02-1.81]; P = .04, respectively) and N3 (HRs, 2.03 [95% CI, 1.40-2.93]; P < .001 and 1.63 [95% CI, 1.17-2.26]; P = .004) disease. Compared with stage II cancer, OS was worse for stage IIIA (HR, 1.65 [95% CI, 1.17-2.31]; P = .004) and stage IIIB (HR, 1.94 [95% CI, 1.34-2.83]; P < .001). Compared with high-volume accrual centers, treatment at low- or middle-volume accrual centers was associated with worse PFS (HRs, 1.94 [95% CI, 1.33-2.82; P < .001] and 1.44 [95% CI, 1.15-1.82; P = .002], respectively) and worse OS (HRs, 1.55 [95% CI, 1.03-2.32; P = .03] and 1.33 [95% CI, 1.04-1.70; P = .02], respectively). Conclusions and Relevance This secondary analysis of the CALGB 30610–RTOG 0538 randomized clinical trial of patients with LS-SCLC found associations between female sex or being younger than 70 years and improved overall survival and between advanced nodal stage or treatment at low- or middle-volume accrual centers and worse outcomes. These findings suggest that stratification by nodal stage, clinical stage, and age should be considered in future randomized trials. Trial Registration ClinicalTrials.gov Identifier: NCT00632853
Comparative analysis of single plane and biplane angiography systems for mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis
Orscelik, Atakan , Bilgin, Cem , Cortese, Jonathan , Cayme, Joshua J , Şenol, Yiğit Can , Musmar, Basel , Ghozy, Sherief , Bayraktar, Esref Alperen , Beizavi, Zahra , Brinjikji, Waleed , Kallmes, David F. , Senol, Yigit Can , Musmar, Basel , Ghozy, Sherief , Bayraktar, Esref Alperen , Brinjikji, Waleed , Orscelik, Atakan , Cortese, Jonathan , Zandpazandi, Sara

Mayo Clinic

Journal of NeuroInterventional Surgery | October 22, 2024 | Volume: 17 | Issue: 6 | Pages: 567-573

10.1136/jnis-2024-022381 | PMID 39438134 Get It

Background The choice of angiography system could influence the outcomes of mechanical thrombectomy (MT) in the treatment of acute ischemic stroke (AIS), but its impact is not yet well understood. This study aims to compare the clinical and technical outcomes of MT performed with single plane versus biplane angiography systems. Method We conducted a systematic review and meta-analysis, following PRISMA guidelines, by searching PubMed, Embase, Web of Science, and Scopus to include studies on patients with AIS who underwent MT with either single plane or biplane angiography up to May 4, 2024. The primary outcome was a favorable outcome defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after the procedure. Data were analyzed using a random-effects model and heterogeneity was assessed using the I2 test and Q statistics. Results Five studies with a total of 1562 patients were analyzed. Of these, 68.4% were treated with biplane systems and 31.6% with single plane systems. Single plane angiography was associated with a significantly higher rate of favorable outcomes (OR 1.43; 95% CI 1.13 to 1.80; P<0.01). There were no significant differences in successful recanalization, periprocedural complications, procedure time, total fluoroscopy time, or contrast volume between the two systems. Conclusion While single plane angiography systems may offer slightly better outcomes in MT for AIS, both systems appear equally effective in most clinical and technical perspectives, suggesting that system selection may be more dependent on availability and procedural requirements rather than inherent superiority. Our findings may encourage clinicians to use single-plane angiography in settings where the biplane angiography suite availability is limited, but it should be noted that this observation may have been influenced by selection bias, particularly since the larger studies included in our meta-analysis did not observe this effect in adjusted analyses for potential confounder factors.
Endovascular therapy versus medical management in isolated posterior cerebral artery acute ischemic stroke: A multinational multicenter propensity score-weighted study
Salim, Hamza , Pulli, Benjamin , Yedavalli, Vivek, Musmar, Basel , Adeeb, Nimer , Lakhani, Dhairya A. , Essibayi, Muhammed Amir , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Grewal, Inayat , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J , Rouchaud, Aymeric, Sheth, Sunil G. , Puri, Ajit S., Dyzmann, Christian , Barreau, Xavier, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent, Gory, Benjamin, Stracke, Christian Paul , Hecker, Constantin, Shaikh, Hamza, Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario, Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien, Investigators, for the MAD MT, Heit, Jeremy J. , Yedavalli, Vivek , Salim, Hamza , Lakhani, Dhairya , Scarcia, Luca , Regenhardt, Robert W , Fiehler, Jens , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Nguyen, Thanh N , Gonzalez, Nestor R , Möhlenbruch, Markus A , Liebeskind, David S. , Alexandre, Andrea M , Faizy, Tobias D , Wintermark, Max , Heit, Jeremy J , Altschul, David J , Musmar, Basel , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Pulli, Benjamin , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil, Puri, Ajit S , Colasurdo, Marco , Barreau, Xavier , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Costalat, Vincent , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Tancredi, Illario , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A. , Investigators, for the MAD MT

Mayo Clinic

European Stroke Journal | October 21, 2024 | Volume: 10 | Issue: 2 | Pages: 387-396

10.1177/23969873241291465 | PMID 39431327 Get It

Abstract Background: Despite the proven effectiveness of endovascular therapy (EVT) in acute ischemic strokes (AIS) involving anterior circulation large vessel occlusions, isolated posterior cerebral artery (PCA) occlusions (iPCAo) remain underexplored in clinical trials. This study investigates the comparative effectiveness and safety of EVT against medical management (MM) in patients with iPCAo. Methods: This multinational, multicenter propensity score-weighted study analyzed data from the Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy (MAD-MT) registry, involving 37 centers across North America, Asia, and Europe. We included iPCAo patients treated with either EVT or MM. The primary outcome was the modified Rankin Scale (mRS) at 90 days, with secondary outcomes including functional independence, mortality, and safety profiles such as hemorrhagic complications. Results: A total of 177 patients were analyzed (88 MM and 89 EVT). EVT showed a statistically significant improvement in 90-day mRS scores (OR = 0.55, 95% CI = 0.30–1.00, p = 0.048), functional independence (OR = 2.52, 95% CI = 1.02–6.20, p = 0.045), and a reduction in 90-day mortality (OR = 0.12, 95% CI = 0.03–0.54, p = 0.006) compared to MM. Hemorrhagic complications were not significantly different between the groups. Conclusion: EVT for iPCAo is associated with better neurological outcomes and lower mortality compared to MM, without an increased risk of hemorrhagic complications. Nevertheless, these results should be interpreted with caution due to the study’s observational design. The findings are hypothesis-generating and highlight the need for future randomized controlled trials to confirm these observations and establish definitive treatment guidelines for this patient population.
Frequency and Genotype‐Dependence of intrinsic chronotropic insufficiency among patients with congenital long QT syndrome
Kulkarni, Veda, Pinsky, Alexa M. , Bos, J. Martijn , Bains, Sahej , Giudicessi, John R. , Allison, Thomas G. , Ackerman, Michael J. , Kulkarni, Veda K, Bains, Sahej , Giudicessi, J R , Ackerman, Michael J , Bos, Johan M , Neves, Raquel

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 21, 2024 | Volume: 36 | Issue: 1 | Pages: 17-23

10.1111/jce.16471 | PMID 39428612 Get It

AbstractIntroductionLong QT syndrome (LQTS) is a cardiac channelopathy characterized by QT prolongation and a potential for arrhythmic syncope, sudden cardiac arrest or deaths (SCA/SCD). It has been speculated that patients with LQTS might have a primary sinoatrial node (SAN) phenotype of chronotropic insufficiency (CI). This has not been demonstrated convincingly before because of the potentially confounding effects of beta blocker (BB) therapy. Herein, we set out to determine whether untreated patients with LQTS demonstrate intrinsic CI.Methods and ResultsA retrospective review of all treadmill exercise stress tests (TEST) was performed on patients with one of the three most common LQTS genotypes: LQT1, LQT2, and LQT3. For each patient, the first TEST completed while off BB was analyzed. Patients with prior left cardiac sympathetic denervation (LCSD) therapy were excluded. CI was defined as having an age‐ and gender‐predicted peak heart rate (HR) < 85% and/or a predicted HR reserve (HRR) < 80%. Overall, 463 LQTS patients (245 LQT1, 125 LQT2, and 93 LQT3) were included (267 female [58%]; mean age at time of TEST [29 ± 17 years]). Mean % predicted peak HR for all LQTS patients was 87.6% (range 42.9% ‐ 119.1%) and mean % predicted HRR was 80% (range 19.1% ‐ 153%). Overall, half of all LQTS patients (n = 234; 51%) displayed CI; 64% of patients with LQT1 (n = 157), 37% with LQT2 (n = 46), and 33% with LQT3 (n = 31). Patients with LQT1 were most likely to exhibit CI compared to patients with LQT2 (p < .0001) and LQT3 (p < .0001). CI was significantly more common in LQT1 compared to controls (p < .0001), while there was no difference between LQT2 (p = .5) or LQT3 and controls (p > .9). Presence of CI was not a predictor of LQTS‐associated symptoms, BB side effects or likelihood of future breakthrough cardiac events (BCE).ConclusionsPatients with LQTS, particularly LQT1, demonstrate a SAN phenotype of CI. If assessing BB therapy effect by impact on peak HR, the patient's pretreatment peak HR, rather than an age‐ and gender‐predicted maximum HR, should be used.
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials
Zouboulis, Christos C. , Kyrgidis, Αthanassios , Alavi, Afsáneh , Wozniak, Magdalena B. , Martinez, Angela Llobet, Kasparek, Torben, Bachhuber, Teresa, Ortmann, Christine-Elke, Lobach, Iryna , Thomas, Nicolas, Ravichandran, Shoba, Kyrgidis, Athanassios , Marzano, Angelo Valerio , Alavi, A , Zouboulis, Christos C , Jemec, Gregor B. E. , Martorell, Antonio , Zee, Hessel H. van der , Lobach, Iryna, Thomas, Nicolas, Tzellos, Thrasyvoulos

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | October 19, 2024 | Volume: 39 | Issue: 8 | Pages: 1421-1430

10.1111/jdv.20369 | PMID 39425517 Get It

AbstractIntroductionThe International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS).ObjectiveTo evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS.MethodsData from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed. Assessments included changes from baseline in IHS4 and severity classification up to Week 52; IHS4‐55, IHS4‐75, IHS4‐90 responses (55%, 75% and 90% reduction in IHS4) and concordance between IHS4‐55 and HS clinical response (HiSCR), at Weeks 16 and 52.ResultsIn total, 1084 patients (SECQ2W = 361; SECQ4W = 360; placebo = 363) were analyzed. At Week 16, SECQ2W and SECQ4W demonstrated a numerically higher reduction in IHS4 from baseline versus placebo (adjusted mean [95% CI]: −10.80 [−12.30 to −9.30] and −9.46 [−10.96 to −7.96] vs. −4.92 [−6.43 to −3.41]); the reduction was maintained until Week 52 in both dose regimens. A greater proportion of patients achieved IHS4‐55 with SECQ2W (43.4%) and SECQ4W (39.5%) versus placebo (31.5%) at Week 16, with further improvement at Week 52. Similar trends were observed for IHS4‐75 and IHS4‐90 responses. While no patients had mild disease based on IHS4 (80.7% had severe and 19.3% had moderate HS) at baseline, a greater proportion of patients were categorized as having mild disease at Week 16 in the SECQ2W (25.9%) and SECQ4W (24.0%) groups versus placebo (16.4%); this trend continued up to Week 52 in both dose regimens. Strong concordance (>85%) was observed between IHS4‐55 and HiSCR.ConclusionsBoth SECQ2W and SECQ4W demonstrated efficacy in improving treatment response as measured by IHS4 and reducing disease severity versus placebo at Week 16 and these improvements were sustained through Week 52. These findings support that the dynamic and dichotomous IHS4 can efficiently detect treatment response changes in clinical trial settings.Clinical Trials RegistrationSUNSHINE (NCT03713619); SUNRISE (NCT03713632).
Promise and Peril of a Genotype‐First Approach to Mendelian Cardiovascular Disease
Asatryan, Babken , Murray, Brittney , Tadros, Rafik , Shah, Ravi A. , Dabbagh, Ghaith Sharaf , Landstrom, Andrew P. , Dobner, Stephan , Munroe, Patricia B. , Haggerty, Christopher M. , Owens, Anjali , Semsarian, Christopher , Barth, Andreas S. , Roden, Dan M. , Ware, James S. , Investigators, the Genotype‐First Approach, Shah, Ravi A , Sharaf Dabbagh, Ghaith , Landstrom, Andrew P , Dobner, Stephan , Munroe, Patricia B , Haggerty, Christopher M , Medeiros-Domingo, Argelia , Owens, Anjali T , Kullo, Iftikhar J , Semsarian, Christopher , Reichlin, Tobias , Barth, Andreas S , Roden, Dan M. , James, Cynthia A , Ware, James S , Chahal, Choudhary Anwar A , Asatryan, Babken , Tadros, Rafik , Rieder, Marina , Medeiros‐Domingo, Argelia , Kullo, Iftikhar J. , James, Cynthia A. , Chahal, C. Anwar A. , Investigators, the Genotype‐First Approach

Mayo Clinic

Journal of the American Heart Association | October 18, 2024 | Volume: 13 | Issue: 21 | Pages: No page available

10.1161/jaha.123.033557 | PMID 39424414 Get It

Precision medicine, which among other aspects includes an individual's genomic data in diagnosis and management, has become the standard‐of‐care for Mendelian cardiovascular disease (CVD). However, early identification and management of asymptomatic patients with potentially lethal and manageable Mendelian CVD through screening, which is the promise of precision health, remains an unsolved challenge. The reduced costs of genomic sequencing have enabled the creation of biobanks containing in‐depth genetic and health information, which have facilitated the understanding of genetic variation, penetrance, and expressivity, moving us closer to the genotype‐first screening of asymptomatic individuals for Mendelian CVD. This approach could transform health care by diagnostic refinement and facilitating prevention or therapeutic interventions. Yet, potential benefits must be weighed against the potential risks, which include evolving variant pathogenicity assertion or identification of variants with low disease penetrance; costly, stressful, and inappropriate diagnostic evaluations; negative psychological impact; disqualification for employment or of competitive sports; and denial of insurance. Furthermore, the natural history of Mendelian CVD is often unpredictable, making identification of those who will benefit from preventive measures a priority. Currently, there is insufficient evidence that population‐based genetic screening for Mendelian CVD can reduce adverse outcomes at a reasonable cost to an extent that outweighs the harms of true‐positive and false‐positive results. Besides technical, clinical, and financial burdens, ethical and legal aspects pose unprecedented challenges. This review highlights key developments in the field of genotype‐first approaches to Mendelian CVD and summarizes challenges with potential solutions that can pave the way for implementing this approach for clinical care.
Dual hypothermic oxygenated machine perfusion of the liver reduces post-transplant biliary complications: a retrospective cohort study
Dingfelder, Jule , Riha, Moriz, Kacar, Sertac, Rauter, Laurin , Becker, Nikolaus , Zadeh, Tina Saffarian, Tortopis, Chiara, Silberhumer, Gerd R. , Soliman, Thomas , Gyöeri, Georg , Pereyra, David , Gyoeri, Georg P , Pereyra, David , Becker, Nikolaus, Starlinger, Patrick , Ristl, Robin , Salat, Andreas , Berlakovich, Gabriela , Györi, Georg

Mayo Clinic

International Journal of Surgery | October 18, 2024 | Volume: 110 | Issue: 12 | Pages: 7909-7918

10.1097/js9.0000000000002115 | PMID 39422535 Get It

Background: Corroborating evidence for the use of hypothermic oxygenated machine perfusion (HOPE) prior to orthotopic liver transplantation (OLT) suggests a beneficial effect in regard to biliary complications. Here, the authors aim to evaluate whether perfusion via portal vein alone (sHOPE) or via additional perfusion of the hepatic artery (dHOPE) have diverging impact on outcomes after OLT when compared to the use of static cold storage (SCS). Methods: Consecutive patients undergoing OLT at the Medical University of Vienna (2018–2023) were retrospectively analyzed. Donor organs were procured using SCS, or subjected to end-ischemic sHOPE or dHOPE. The severity of biliary complications was classified according to the degree of therapeutic intervention (endoscopic retrograde cholangiopancreatography or surgical revision). Results: Two hundred forty-seven patients were included (69 SCS, 76 sHOPE, and 102 dHOPE). Hospitalization was shorter for patients after HOPE (median in days: SCS=25 vs HOPE=20, P=0.019). Biliary complications were less frequent in patients after HOPE (SCS=37.7% vs HOPE=22.5%, P=0.015). A significantly lower incidence of surgical revisions for biliary complications was observed in the HOPE cohort (24.6% vs 11.8%, P=0.012). When evaluating outcome according to HOPE-modality, a significant reduction in biliary complications (P=0.006) and surgical revisions (P=0.002) was only observed in dHOPE patients in comparison to SCS. Further, only dHOPE was significantly associated with a reduced need for surgical revision for biliary complications upon univariable and multivariable logistic regression (odds ratio=0.336, P=0.011). Conclusion: HOPE leads to a reduction of biliary complications and associated surgical revisions. This effect seems to be primarily associated with use of dHOPE, while both methods appear as feasible options for preconditioning of donor grafts prior to OLT.
Three-Year Outcomes Following TAVR in Younger (
Modine, Thomas , Tchétché, Didier , Mieghem, Nicolas M. Van , Deeb, G. Michael , Chetcuti, Stanley, Yakubov, Steven J. , Sorajja, Paul , Gada, Hemal, Mumtaz, Mubashir , Ramlawi, Basel , Bajwa, Tanvir , Crouch, John , Teirstein, Paul S., Kleiman, Neal S. , Iskander, Ayman, Chu, Michael , Sudre, Arnaud , Huang, Jian, Popma, Jeffrey J. , Forrest, John K. , Van Mieghem, Nicolas M , Bagur, Rodrigo , Chu, Michael W A , Berthoumieu, Pierre , Sudre, Arnaud , Adrichem, Rik , Ito, Saki , Forrest, John K , Modine, Thomas , Sorajja, Paul , Bagur, Rodrigo , Ito, Saki , Huang, Jian Qun , Reardon, Michael J.

Mayo Clinic

Circulation: Cardiovascular Interventions | October 18, 2024 | Volume: 17 | Issue: 11 | Pages: No page available

10.1161/circinterventions.124.014018 | PMID 39421943 Get It

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis, but data are limited on younger, low-risk patients. This analysis compares outcomes in low-surgical-risk patients aged <75 years receiving TAVR versus surgery. METHODS: The Evolut Low Risk Trial randomized 1414 low-risk patients to treatment with a supra-annular, self-expanding TAVR or surgery. We compared rates of all-cause mortality or disabling stroke, associated clinical outcomes, and bioprosthetic valve performance at 3 years between TAVR and surgery patients aged <75 years. RESULTS: In patients <75 years, 352 were randomized to TAVR and 351 to surgery. Mean age was 69.1±4.0 years (minimum 51 and maximum 74); Society of Thoracic Surgeons Predicted Risk of Mortality was 1.7±0.6%. At 3 years, all-cause mortality or disabling stroke for TAVR was 5.7% and 8.0% for surgery ( P =0.241). Although there was no difference between TAVR and surgery in all-cause mortality, the incidence of disabling stroke was lower with TAVR (0.6%) than surgery (2.9%; P =0.019), while surgery was associated with a lower incidence of pacemaker implantation (7.1%) compared with TAVR (21.0%; P <0.001). Valve reintervention rates (TAVR 1.5%, surgery 1.5%, P =0.962) were low in both groups. Valve performance was significantly better with TAVR than surgery with lower mean aortic gradients ( P <0.001) and lower rates of severe prosthesis-patient mismatch ( P <0.001). Rates of valve thrombosis and endocarditis were similar between groups. There were no significant differences in rates of residual ≥moderate paravalvular regurgitation. CONCLUSIONS: Low-risk patients <75 years treated with supra-annular, self-expanding TAVR had comparable 3-year all-cause mortality and lower disabling stroke compared with patients treated with surgery. There was significantly better valve performance in patients treated with TAVR. REGISTRATION: URL: https://clinicaltrials.gov ; Unique identifier: NCT02701283.
Development of a Uniform Apheresis Case Report Form for Standardized Collection of Apheresis Data
Johnson, Andrew D., Szczepiorkowski, Zbigniew M. , Karam, Oliver , Nellis, Marianne E. , Schwartz, Joseph, Wu, Yanyun , Armendariz, Tomas , Burgstaler, Edwin A. , Collins, Laura , Geile, Kira, Pavenski, Katerina , Sanchez, Amber P. , Witt, Volker, Muthusamy, Amutha, Ramesh, Vidhyalakshmi , Thao, Mai See , Chlebeck, Therese M., Zantek, Nicole D. , Karam, Oliver , Armendariz, Tomas , Burgstaler, Edwin, Zantek, Nicole D , Balogun, Rasheed A. , Schneiderman, Jennifer , Winters, Jeffrey L. , Pavenski, Katerina , Pederson, Thomas

Mayo Clinic

Journal of Clinical Apheresis | October 18, 2024 | Volume: 39 | Issue: 5 | Pages: No page available

10.1002/jca.22146 | PMID 39420527 Get It

ABSTRACTApheresis is performed worldwide for an increasing number of indications. The development of common data elements (CDE) for apheresis related areas may facilitate conduct of new research, enhance quality initiatives including benchmarking, and improve patient care. This report describes the systematic development of the Uniform Apheresis Case Report Form (UACRF) as part of the Apheresis in the United States (ApheresUS) program. A consensus panel of 17 diverse experts in apheresis, related specialties, and electronic case report form (eCRF), and database development was assembled. The panel met via online conferencing from November 17, 2020 to December 1, 2021. A draft document was posted online for public comment from October 11, 2021 to November 10, 2021. Feedback was collected using an online survey tool. The consensus panel revised the UACRF. This version was converted to an eCRF with additional changes made to improve usability in this format. The final version of the UACRF was created on August 24, 2023. The UACRF contains 16 modules: procedure and subject eligibility, patient demographics, general procedure information, laboratory parameters, vascular access, common procedure elements, eight procedure specific modules (mononuclear cell collection and seven therapeutic modalities), outcomes, and site information. A total of 137 data elements were created, including 57 with one or more subelements. The UACRF is the first systematic attempt to develop CDE for therapeutic apheresis and white blood cell collections. Further validation of the UACRF is necessary to confirm the tool's ability to collect the relevant data elements and determine the usability of the form.